Literature DB >> 35111633

Impact of point-spread function reconstruction on dynamic and static 18F-DOPA PET/CT quantitative parameters in glioma.

Antoine Girard1, Madani François2, Nibras Chaboub2, Pierre-Jean Le Reste3, Anne Devillers2, Hervé Saint-Jalmes2, Florence Le Jeune1, Xavier Palard-Novello2.   

Abstract

BACKGROUND: Quantification of dynamic and static parameters extracted from 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA, FDOPA) positron emission tomography (PET)/computed tomography (CT) plays a critical role for glioma assessment. The objective of the present study was to investigate the impact of point-spread function (PSF) reconstruction on these quantitative parameters.
METHODS: Fourteen patients with untreated gliomas and investigated with FDOPA PET/CT were analyzed. The distribution of the 14 cases was as follows: 6 astrocytomas-isocitrate dehydrogenase-mutant; 2 oligodendrogliomas/1p19q-codeleted-isocitrate dehydrogenase-mutant; and 6 isocitrate dehydrogenase-wild-type glioblastomas. A 0-20-min dynamic images (8×15, 2×30, 2×60, and 3×300 s post-injection) and a 0-20-min static image were reconstructed with and without PSF. Tumoral volumes-of-interest were generated on all of the PET series and the background volumes-of-interest were generated on the 0-20-min static image with and without PSF. Static parameters (SUVmax and SUVmean) of the tumoral and the background volumes-of-interest and kinetic parameters (K1 and k2) of the tumoral volumes-of-interest extracted from using full kinetic analysis were provided. PSF and non-PSF quantitative parameters values were compared.
RESULTS: Thirty-three tumor volumes-of-interest and 14 background volumes-of-interest were analyzed. PSF images provided higher tumor SUVmax than non-PSF images for 23/33 VOIs [median SUVmax =3.0 (range, 1.4-10.2) with PSF vs. 2.7 (range, 1.4-9.1) without PSF; P<0.001] and higher tumor SUVmean for 13/33 volumes-of-interest [median SUVmean =2.0 (range, 0.8-7.6) with PSF vs. 2.0 (range, 0.8-7.4) without PSF; P=0.002]. K1 and k2 were significantly lower with PSF than without PSF [respectively median K1 =0.077 mL/ccm/min (range, 0.043-0.445 mL/ccm/min) with PSF vs. 0.101 mL/ccm/min (range, 0.055-0.578 mL/ccm/min) without PSF; P<0.001 and median k2 =0.070 min-1 (range, 0.025-0.146 min-1) with PSF vs. 0.081 min-1 (range, 0.027-0.180 min-1) without PSF; P<0.001]. Background SUVmax and SUVmean were statistically unaffected [respectively median SUVmax =1.7 (range, 1.3-2.0) with PSF vs. 1.7 (range, 1.3-1.9) without PSF; P=0.346 and median SUVmean =1.5 (range, 1.0-1.8) with PSF vs. 1.5 (range, 1.0-1.7) without PSF; P=0.371].
CONCLUSIONS: The present study confirms that PSF significantly increases tumor activity concentrations measured on PET images. PSF algorithms for quantitative PET/CT analysis should be used with caution, especially for quantification of kinetic parameters. 2022 Quantitative Imaging in Medicine and Surgery. All rights reserved.

Entities:  

Keywords:  3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (FDOPA); gliomas; kinetic; point-spread function (PSF); positron emission tomography (PET)

Year:  2022        PMID: 35111633      PMCID: PMC8739156          DOI: 10.21037/qims-21-742

Source DB:  PubMed          Journal:  Quant Imaging Med Surg        ISSN: 2223-4306


  33 in total

1.  Impact of point spread function reconstruction on thoracic lymph node staging with 18F-FDG PET/CT in non-small cell lung cancer.

Authors:  Charline Lasnon; Rodney J Hicks; Jean-Mathieu Beauregard; Alvin Milner; Maria Paciencia; Anne-Valérie Guizard; Stéphane Bardet; Radj Gervais; Gabriel Lemoel; Gérard Zalcman; Nicolas Aide
Journal:  Clin Nucl Med       Date:  2012-10       Impact factor: 7.794

2.  Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.

Authors:  Constantin Lapa; Thomas Linsenmann; Camelia Maria Monoranu; Samuel Samnick; Andreas K Buck; Christina Bluemel; Johannes Czernin; Almuth F Kessler; Gyoergy A Homola; Ralf-Ingo Ernestus; Mario Löhr; Ken Herrmann
Journal:  J Nucl Med       Date:  2014-08-14       Impact factor: 10.057

3.  Impact of [¹⁸F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology.

Authors:  Patsuree Cheebsumon; Maqsood Yaqub; Floris H P van Velden; Otto S Hoekstra; Adriaan A Lammertsma; Ronald Boellaard
Journal:  Eur J Nucl Med Mol Imaging       Date:  2011-08-20       Impact factor: 9.236

4.  Clinical impact of time-of-flight and point response modeling in PET reconstructions: a lesion detection study.

Authors:  Joshua Schaefferkoetter; Michael Casey; David Townsend; Georges El Fakhri
Journal:  Phys Med Biol       Date:  2013-02-13       Impact factor: 3.609

5.  Modelling approach for separating blood time-activity curves in positron emission tomographic studies.

Authors:  S C Huang; J R Barrio; D C Yu; B Chen; S Grafton; W P Melega; J M Hoffman; N Satyamurthy; J C Mazziotta; M E Phelps
Journal:  Phys Med Biol       Date:  1991-06       Impact factor: 3.609

6.  Brain PET imaging optimization with time of flight and point spread function modelling.

Authors:  Elena Prieto; Josep M Martí-Climent; Verónica Morán; Lidia Sancho; Benigno Barbés; Javier Arbizu; Jose A Richter
Journal:  Phys Med       Date:  2015-08-04       Impact factor: 2.685

7.  Influences of point-spread function and time-of-flight reconstructions on standardized uptake value of lymph node metastases in FDG-PET.

Authors:  Go Akamatsu; Katsuhiko Mitsumoto; Takafumi Taniguchi; Yuji Tsutsui; Shingo Baba; Masayuki Sasaki
Journal:  Eur J Radiol       Date:  2013-10-06       Impact factor: 3.528

8.  Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0.

Authors:  Ian Law; Nathalie L Albert; Javier Arbizu; Ronald Boellaard; Alexander Drzezga; Norbert Galldiks; Christian la Fougère; Karl-Josef Langen; Egesta Lopci; Val Lowe; Jonathan McConathy; Harald H Quick; Bernhard Sattler; David M Schuster; Jörg-Christian Tonn; Michael Weller
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-12-05       Impact factor: 9.236

9.  Additive Value of Dynamic FDOPA PET/CT for Glioma Grading.

Authors:  Antoine Girard; Pierre-Jean Le Reste; Alice Metais; Nibras Chaboub; Anne Devillers; Hervé Saint-Jalmes; Florence Le Jeune; Xavier Palard-Novello
Journal:  Front Med (Lausanne)       Date:  2021-07-09

10.  Diagnostic and grading accuracy of 18F-FDOPA PET and PET/CT in patients with gliomas: a systematic review and meta-analysis.

Authors:  Jiarui Xiao; Yizi Jin; Ji Nie; Fukun Chen; Xuelei Ma
Journal:  BMC Cancer       Date:  2019-08-05       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.